CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 4,748 enrolled
Drug / intervention
Vytorin (R) (Ezetimibe + Simvastatin)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00909389
NCT00909389N/ACompleted
CompareCT.gov

Post - Marketing Surveillance of the Safety, Tolerability and Efficacy of Vytorin (Ezetimibe + Simvastatin) Tablet Among Filipino Patients

Organon and Co·observational·Posted May 28, 2009·Updated Feb 9, 2022

In Brief

An observational study evaluating Vytorin (R) (Ezetimibe + Simvastatin) for Hypercholesterolemia. Completed, enrolled 4,748 participants.

Detailed Summary

This study aims to establish the safety, tolerability, and efficacy of Vytorin (R) (Ezetimibe + Simvastatin) (SCH 465981) on a select population of Filipinos with hypercholesterolemia.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsHypercholesterolemia
Countries--
Collaborators--

Timeline

N/ACompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 28, 2009
Enrollment StartNov 1, 2006
Primary CompletionNov 1, 2008
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 17.1 years ago

Interventions

Vytorin (R) (Ezetimibe + Simvastatin)drug

Vytorin (R) (Ezetimibe + Simvastatin) 1 tablet once daily to be taken by mouth in the evening for 28 days